Targets › ADRB2
113 programs from 98 companies in 215 trials: 68 Phase 4, 66 Phase 2, 41 Phase 3, 40 Phase 1; Cardiovascular, Respiratory, Other; next expected readout Nov 2026.
G protein-coupled receptor for catecholamines that couples to both G(s) and G(i) proteins, activating bifurcated signaling pathways. ADRB2 binds epinephrine (Epi) with an approximately 30-fold greater affinity than norepinephrine (NE). (UniProt, P07550)
Open in Phaseline: the race on ADRB2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Yongtao Sun | Esmolol Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist | ADRB1, ADRB2 | Phase 4 | Frailty | Nov 2026 |
| University of California, San Francisco | Intravenous TXA Interleukin-23 inhibitor | ADRB2, AGTR1, IL12B, IL23A, PDCD1, NR3C1, HTR2A, MAP2K1, MAP2K2, MS4A1, CHRM3, CHRM2, ADRB3, OPRM1, CYP19A1, CHRNB2, CHRNA4 | Phase 4 | Child Mortality; Relapsing Multiple Sclerosis; Menstrual Regulation; Secondhand Smoke … | Dec 2026 |
| University of Calgary | CBD 100 mg OD Interleukin-23 inhibitor | CNR1, PLAT, IL12B, IL23A, ADRB2, HTR2A, NR3C1, TNF, PTGS2, PTGS1 | Phase 4 | Copd; Ehlers-Danlos Syndrome; Crohn Disease; Vasovagal Syncope … | Dec 2026 |
| King's College Hospital NHS Trust | Carvedilol Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist | ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1D | Phase 4 | Cirrhosis, Liver | Dec 2026 |
| Ottawa Heart Institute Research Corporation | Dobutamine Beta-1 adrenergic receptor agonist; Beta-2 adrenergic receptor agonist | ADRB1, ADRB2 | Phase 4 | Shock, Cardiogenic | Dec 2026 |
| Cairo University | Ephedrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 4 | Incidence of Post-spinal Hypotension | Dec 2026 |
| Mansoura University | Ephedrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 4 | Cesarean Delivery | Dec 2026 |
| Mansoura University | Norepinephrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 4 | Cesarean Delivery | Dec 2026 |
| Dr. J. Alberto Neder | Salbutamol sulphate Beta-2 adrenergic receptor agonist | ADRB2 | Phase 4 | COPD | Jan 2027 |
| AstraZeneca | Albuterol Beta-2 adrenergic receptor agonist | ADRB2 | Phase 4 | Asthma | Feb 2027 |
| University of North Carolina, Chapel Hill | Propranolol Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist | ADRB1, ADRB2 | Phase 4 | Cardiovascular Disease | Feb 2027 |
| Sohag University | Norepinephrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 4 | Patients Undergoing Orthopedic Hip Surgery Under Spinal Anesthesia | Mar 2027 |
| University of Oklahoma | Propranolol Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist | ADRB1, ADRB2 | Phase 4 | Tobacco Use Disorder | Mar 2027 |
| ARS Pharmaceuticals | Epinephrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 4 | Allergic Reactions; Knee Arthroplasty, Total; Cardiac Arrest, Out-Of-Hospital; Shock Hypovolemic … | Apr 2027 |
| Icahn School of Medicine at Mount Sinai | Ephedrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 4 | Labor | May 2027 |
| Hospital Sirio-Libanes | Carvedilol Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist | ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1D | Phase 4 | Cancer | May 2027 |
| James J. Peters Veterans Affairs Medical Center | Droxidopa Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 4 | Hypotension | Jun 2027 |
| University of California, Davis | Norepinephrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 4 | Hypotension and Shock | Jun 2027 |
| Aarhus University Hospital | Labetalol Adrenergic receptor antagonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 4 | Intracerebral Haemorrhage | Sep 2027 |
| University of Alberta | Norepinephrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 4 | Vasoconstriction | Dec 2027 |
| AstraZeneca | Breztri Aerosphere Triple combination: inhaled corticosteroid (budesonide) + long-acting muscarinic antagonis | ADRB2, CHRM3 | Phase 4 | Moderate to Severe COPD | Dec 2027 |
| University Hospital, Limoges | Esmolol Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist | ADRB1, ADRB2 | Phase 4 | Laparoscopic Cholecystectomy Surgery | Jan 2028 |
| University of Miami | Albuterol-Budesonide (AIRSUPRA) Fast-acting beta-2 agonist and inhaled corticosteroid combination | ADRB2, GR | Phase 4 | Asthma | Apr 2028 |
| Chiesi Farmaceutici | Formoterol Beta-2 adrenergic receptor agonist | ADRB2 | Phase 4 | Asthma | Jun 2028 |
| Post Graduate Institute of Medical Education and Research, Chandigarh | Carvedilol Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist | ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1D | Phase 4 | Cirrhotic Cardiomyopathy | Jan 2029 |
| Taipei Veterans General Hospital, Taiwan | Carvedilol Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist | ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1D | Phase 4 | Hepatocellular Carcinoma (HCC); Cirrhosis | Oct 2030 |
| University of Rochester | Carvedilol Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist | ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1D | Phase 4 | Heart Failure With Reduced Ejection Fraction (HFrEF) | Jun 2031 |
| Chinese University of Hong Kong | Carvedilol Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist | ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1D | Phase 4 | Portal Hypertension | Jul 2031 |
| Bo Gregers Winkel | Nadolol Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist | ADRB1, ADRB2 | Phase 4 | Idiopathic Ventricular Fibrillation | Dec 2032 |
| Bo Gregers Winkel | Propranolol Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist | ADRB1, ADRB2 | Phase 4 | Idiopathic Ventricular Fibrillation | Dec 2032 |
| Bispebjerg Hospital | Carvedilol Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist | ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1D | Phase 4 | Acute Myocardial Infarction | Dec 2035 |
| Bispebjerg Hospital | Nebivolol Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist | ADRB1, ADRB2 | Phase 4 | Acute Myocardial Infarction | Dec 2035 |
| Dalian Municipal Central Hospital | Ephedrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 4 | Hypotension Drug-Induced | – |
| Nebraska Methodist Health System | Labetalol Adrenergic receptor antagonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 4 | Postpartum Preeclampsia | – |
| Tunis University | Norepinephrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 4 | Sepsis, Severe | – |
| Dalian Municipal Central Hospital | Norepinephrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 4 | Hypotension Drug-Induced | – |
| Hassan II University | Norepinephrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 4 | Cesarean Section Complications | – |
| Massachusetts General Hospital | Propranolol Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist | ADRB1, ADRB2 | Phase 4 | Stress Disorders, Post-Traumatic | – |
| Walter Reed Army Institute of Research (WRAIR) | Propranolol Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist | ADRB1, ADRB2 | Phase 4 | Fear of Spiders | – |
| University of Illinois Chicago | Sotalol Beta-1 adrenergic receptor antagonist; HERG blocker; Beta-2 adrenergic receptor antagonist | ADRB1, Ion channels, ADRB2 | Phase 4 | Atrial Fibrillation | – |
| Federal University of São Paulo | Triplenex (triple fixed combination) Triple combination: alpha-2 adrenergic agonist (brimonidine), non-selective beta-blocker ( | ADRA2A, ADRB1, ADRB2, PTGFR | Phase 4 | Glaucoma | – |
| Beni-Suef University | Ventoline® Evohaler® 100 µg/inhalation pMDI Beta-2 adrenergic receptor agonist | ADRB2 | Phase 4 | Asthmatic Patients | – |
| University of Texas Southwestern Medical Center | propranolol Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist | ADRB1, ADRB2 | Phase 4 | Heat Stress | – |
| NHS Greater Glasgow and Clyde | Norepinephrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 3 | Sepsis | Nov 2026 |
| Mahidol University | Vilanterol Beta-2 adrenergic receptor agonist | ADRB2 | Phase 3 | COPD | Dec 2026 |
| Odense University Hospital | Norepinephrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 3 | Shock | Dec 2026 |
| Teva Branded Pharmaceutical Products R&D | TEV-56248 Fixed-dose combination of inhaled corticosteroid (fluticasone propionate) and beta-2 agoni | ADRB2 | Phase 3 | Asthma | Dec 2026 |
| GSK | FF/UMEC/VI Inhaled corticosteroid/muscarinic antagonist/long-acting beta-2 agonist combination | CHRM3, ADRB2 | Phase 3 | Asthma | Jan 2027 |
| Consorcio Centro de Investigación Biomédica en Red (CIBER) | Esmolol Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist | ADRB1, ADRB2 | Phase 3 | Cirrhosis | Mar 2027 |
| Jagiellonian University | Norepinephrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 3 | Blood Pressure Management | Jun 2027 |
| Hospital do Coracao | Norepinephrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 3 | Septic Shock | Aug 2027 |
| University Hospital, Bordeaux | Norepinephrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 3 | Stroke, Acute | Aug 2027 |
| University Hospital, Toulouse | Propranolol Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist | ADRB1, ADRB2 | Phase 3 | PTSD | Sep 2027 |
| University of Monastir | Terbutaline Beta-2 adrenergic receptor agonist | ADRB2 | Phase 3 | Renal Colic | Dec 2027 |
| AstraZeneca | BGF MDI 320/14.4/9.6 μg Triple therapy: inhaled corticosteroid (budesonide) + long-acting muscarinic antagonist (g | ADRB2, CHRM3 | Phase 3 | COPD (Chronic Obstructive Pulmonary Disease) | Dec 2027 |
| Loma Linda University | Labetalol Adrenergic receptor antagonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 3 | Postpartum Complication | Dec 2027 |
| Novartis | Indacaterol (QVM149) Beta-2 adrenergic receptor agonist | ADRB2 | Phase 3 | Asthma | Feb 2028 |
| Fundació d'investigació Sanitària de les Illes Balears | Propranolol Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist | ADRB1, ADRB2 | Phase 3 | Traumatic Brain Injury (TBI) Patients | Jun 2028 |
| Lunan Better Pharmaceutical | Formoterol Beta-2 adrenergic receptor agonist | ADRB2 | Phase 3 | Asthma (Diagnosis) | Jun 2028 |
| Chiesi Farmaceutici | CHF 5993 100/6/12.5 μg pMDI HFA-152a Triple combination of inhaled corticosteroid, long-acting beta-2 agonist, and long-acting | ADRB2, CHRM3 | Phase 3 | Asthma | Oct 2028 |
| Acer Therapeutics | Celiprolol (ACER-002) Beta-2 adrenergic receptor partial agonist; Adrenergic receptor alpha-2 antagonist; Beta-1 adrenergic receptor antagonist | ADRB2, ADRA2A, ADRA2C, ADRA2B, ADRB1 | Phase 3 | Vascular Ehlers-Danlos Syndrome | Mar 2029 |
| SWOG Cancer Research Network | Carvedilol Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist | ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1D | Phase 3 | Cardiotoxicity | Jun 2031 |
| Ain Shams University | Carvedilol Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist | ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1D | Phase 3 | Cardiotoxicity | – |
| University of Turin, Italy | Norepinephrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 3 | Critical Illness | – |
| Samsung Medical Center | Vilanterol Beta-2 adrenergic receptor agonist | ADRB2 | Phase 3 | Chronic Obstructive Pulmonary Disease | – |
| Emory University | Propranolol Hydrochloride Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist | ADRB1, ADRB2 | Phase 2 | Locally Advanced Bladder Urothelial Carcinoma; Anatomic Stage III Breast Cancer AJCC v8 | Dec 2026 |
| Medical University of South Carolina | Formoterol fumarate Beta-2 adrenergic receptor agonist | ADRB2 | Phase 2 | Diabetic Nephropathies | Dec 2026 |
| Stanford University | Nebivolol Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist | ADRB1, ADRB2 | Phase 2 | Angina Pectoris | Dec 2026 |
| Morten Hostrup, PhD | ATR-258 GRK-selective long-acting β2-agonist | ADRB2 | Phase 2 | Overweight and Obesity | Dec 2026 |
| Zealand University Hospital | Propranolol Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist | ADRB1, ADRB2 | Phase 2 | Pancreatic Cancer | Dec 2026 |
| Huashan Hospital | propranolol Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist | ADRB1, ADRB2 | Phase 2 | Gastrointestinal Tumors | Dec 2026 |
| Ain Shams University | Nebivolol Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist | ADRB1, ADRB2 | Phase 2 | HER2-positive Breast Cancer | Feb 2027 |
| Assaf-Harofeh Medical Center | Propranolol Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist | ADRB1, ADRB2 | Phase 2 | Colorectal Neoplasms | Feb 2027 |
| Actimed Therapeutics | Pindolol (ACM-001) Beta-1 adrenergic receptor partial agonist; Beta-2 adrenergic receptor partial agonist | ADRB1, ADRB2 | Phase 2 | Obesity | Mar 2027 |
| West China Hospital | propranolol Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist | ADRB1, ADRB2 | Phase 2 | Infantile Hemangioma | Mar 2027 |
| AHS Cancer Control Alberta | Propranolol Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist | ADRB1, ADRB2 | Phase 2 | Pancreatic Cancer | May 2027 |
| Chiesi Farmaceutici | CHF5993 pMDI 100/6/12.5 µg with HFA-152a Triple combination: inhaled corticosteroid (ICS), long-acting beta-2 agonist (LABA), long- | ADRB2, CRHR1 | Phase 2 | Asthma | Jun 2027 |
| Gianni Soraru | Clenbuterol Beta-2 adrenergic receptor agonist | ADRB2 | Phase 2 | Spinal and Bulbar Muscular Atrophy | Jun 2027 |
| University of Aarhus | Norepinephrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 2 | Hypotension | Dec 2027 |
| Giuseppe Cullaro, MD | Droxidopa Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 2 | Acute Kidney Injury | Dec 2027 |
| Niels Junker | Propranolol Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist | ADRB1, ADRB2 | Phase 2 | Soft Tissue Sarcoma Adult | Jan 2028 |
| University of Virginia | Anoro Ellipta Long-acting muscarinic antagonist (umeclidinium) + long-acting beta-2 agonist (vilanterol) | CHRM3, ADRB2 | Phase 2 | Chronic Obstructive Pulmonary Disease | Jan 2028 |
| AIDS Malignancy Consortium | Propranolol Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist | ADRB1, ADRB2 | Phase 2 | Kaposi Sarcoma | Sep 2028 |
| Jeremy Veenstra-vanderweele | Propranolol Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist | ADRB1, ADRB2 | Phase 2 | Autism Spectrum Disorder | Nov 2028 |
| University of Zurich | Propranolol Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist | ADRB1, ADRB2 | Phase 2 | Retinopathy of Prematurity | Dec 2028 |
| Roswell Park Cancer Institute | Propranolol Hydrochloride Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist | ADRB1, ADRB2 | Phase 2 | Clinical Stage II Esophageal Adenocarcinoma AJCC v8; Esophageal Adenocarcinoma | Mar 2029 |
| University of Alberta | Dobutamine Beta-1 adrenergic receptor agonist; Beta-2 adrenergic receptor agonist | ADRB1, ADRB2 | Phase 2 | Hypoxic-ischemic Encephalopathy (HIE) | Apr 2029 |
| Sherief Abd-Elsalam | Carvedilol Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist | ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1D | Phase 2 | Esophageal Varices | Dec 2030 |
| Michele Tagliati, MD | Carvedilol Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist | ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1D | Phase 2 | REM Sleep Behavior Disorder | – |
| Cedars-Sinai Medical Center | Carvedilol Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist | ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1D | Phase 2 | REM Sleep Behavior Disorder | – |
| Copenhagen University Hospital, Rigshospitalet | Dobutamine Beta-1 adrenergic receptor agonist; Beta-2 adrenergic receptor agonist | ADRB1, ADRB2 | Phase 2 | Acute Myocardial Infarction | – |
| St. John's Research Institute | Nebivolol Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist | ADRB1, ADRB2 | Phase 2 | Diabetic Neuropathy Peripheral | – |
| Tel-Aviv Sourasky Medical Center | Propranolol Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist | ADRB1, ADRB2 | Phase 2 | Ovarian Cancer | – |
| Kingston Health Sciences Centre | dobutamine Beta-1 adrenergic receptor agonist; Beta-2 adrenergic receptor agonist | ADRB1, ADRB2 | Phase 2 | Shock | – |
| Kingston Health Sciences Centre | norepinephrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 2 | Shock | – |
| University of Colorado, Denver | Salmeterol Beta-2 adrenergic receptor agonist | ADRB2 | Phase 1 | Altitude Edema | Dec 2026 |
| Geriatric Hospital of Nanjing Medical University | Norepinephrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 1 | Urolithiasis | Dec 2026 |
| Polarean | Albuterol Sulfate Beta-2 adrenergic receptor agonist | ADRB2 | Phase 1 | Chronic Obstructive Pulmonary Disease; Bronchiolitis | Dec 2026 |
| University of Alabama at Birmingham | Labetalol Adrenergic receptor antagonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 1 | Hypertension in Pregnancy | Dec 2026 |
| Second Xiangya Hospital of Central South University | Propranolol hydrochloride Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist | ADRB1, ADRB2 | Phase 1 | Non Small Cell Lung Cancer; Resectable Non-Small-Cell Lung Cancer; Small Cell Lung Cancer (SCLC) | Dec 2026 |
| EyeD Pharma | Timolol Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist | ADRB1, ADRB2 | Phase 1 | Glaucoma | Jan 2027 |
| Icahn School of Medicine at Mount Sinai | Timolol Maleate Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist | ADRB1, ADRB2 | Phase 1 | Wound Healing | Jan 2027 |
| GSK | Albuterol Beta-2 adrenergic receptor agonist | ADRB2 | Phase 1 | Asthma; TTN; Lymphangioleiomyomatosis | Apr 2027 |
| Steen Hvitfeldt Poulsen | Dobutamine Beta-1 adrenergic receptor agonist; Beta-2 adrenergic receptor agonist | ADRB1, ADRB2 | Phase 1 | ATTR Amyloidosis Wild Type | Sep 2027 |
| Sarah Weiss | Propranolol Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist | ADRB1, ADRB2 | Phase 1 | Advanced Melanoma | Sep 2027 |
| Jeffrey Statland | Clenbuterol Beta-2 adrenergic receptor agonist | ADRB2 | Phase 1 | Muscular Dystrophy, Facioscapulohumeral | Feb 2028 |
| Instituto de Investigación Hospital Universitario La Paz | Dobutamine Beta-1 adrenergic receptor agonist; Beta-2 adrenergic receptor agonist | ADRB1, ADRB2 | Phase 1 | Infant, Premature, Diseases | Jun 2029 |
| Satish R. Raj | Propranolol Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist | ADRB1, ADRB2 | Phase 1 | Tachycardia | Dec 2029 |
| Stephen G. Kaler | Droxidopa Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 1 | Menkes Disease | Jun 2030 |
| Brigham and Women's Hospital | Norepinephrine Adrenergic receptor agonist | ADRA1A, ADRA2A, ADRB1, ADRB2, ADRA2C | Phase 1 | Hypertension | – |
| University Hospital, Lille | TRIXEO AEROSPHERE (BGF 160) Fixed triple combination: long-acting beta-2 agonist (formoterol), long-acting muscarinic | ADRB2, CHRM3, NR3C1 | Phase 1 | Copd | – |
| Mansoura University | carvedilol Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist | ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1D | Phase 1 | TBI Traumatic Brain Injury | – |
| Mansoura University | propranolol Beta-1 adrenergic receptor antagonist; Beta-2 adrenergic receptor antagonist | ADRB1, ADRB2 | Phase 1 | TBI Traumatic Brain Injury | – |
Asthma (12) Shock (4) Acute Myocardial Infarction (3) Chronic Obstructive Pulmonary Disease (3) Nicotine Dependence (3) COPD (2) Pancreatic Cancer (2) Glaucoma (2) Cesarean Delivery (2) Cirrhosis (2) Hypotension (2) Cardiotoxicity (2)
small molecule (100), mixed (8)
Mansoura University (4) Chiesi Farmaceutici (3) AstraZeneca (3) Icahn School of Medicine at Mount Sinai (2) Ain Shams University (2) University of Alberta (2) GSK (2) Dalian Municipal Central Hospital (2) Bispebjerg Hospital (2) Kingston Health Sciences Centre (2) Bo Gregers Winkel (2) Mahidol University (1) Zealand University Hospital (1) University of Oklahoma (1) Nebraska Methodist Health System (1) Copenhagen University Hospital, Rigshospitalet (1) Fundació d'investigació Sanitària de les Illes Balears (1) Federal University of São Paulo (1) Hospital do Coracao (1) Stanford University (1)
ADRB1 (86) ADRA1A (42) ADRA2A (31) ADRA2C (30) ADRB3 (14) ADRA1D (13) CHRM3 (7) NR3C1 (3) IL12B (2) IL23A (2) HTR2A (2) PTGFR (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.